Marsh & McLennan Companies, Inc. · MRSH · FY2026 Q1 · Calendar Q2 2026

Marsh tops Q1 estimates on 8% revenue growth; AI push and AltamarCAM set 2026 tone

Marsh's Q1 print shows a business able to grow adjusted EPS and expand margins even as insurance and reinsurance pricing compresses, aided by AI-driven productivity, an active acquisition pipeline (AltamarCAM) and steady capital returns. The test over the coming year is whether underlying revenue growth near 4% and margin expansion can outpace falling pricing, lower fiduciary income and the drag from the $425M litigation charge.

Reported Before market openNYSEFinancial Services $81.09B market cap
100quality score

Earnings scorecard

Reported versus consensus
Reported EPS $3.29 Consensus $3.22
EPS surprise +2.2% Reported versus consensus
Reported revenue $7.60B Consensus $7.41B
Revenue surprise +2.6% Reported versus consensus

Market reaction

prior-close to event-session close
Stock move +4.4% Event window
SPY move +0.2% Same window
Abnormal move +4.1% Stock minus SPY
Volume 1.3× Versus trailing sessions
Subsequent drift -12.4% Up to 20 sessions
MRSHSPY benchmark

Ask FN2 about MRSH FY2026 Q1

Transcript, numbers and history already loaded
Why did MRSH rise 4.4% after beating EPS estimates in FY2026 Q1?What changed in MRSH's guidance and outlook in FY2026 Q1?Give me the bull and bear case for MRSH after FY2026 Q1 earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Transcript intelligence

What changed

Compared with the prior quarter (Q4 2025 revenue +9%), Q1 2026 revenue grew 8% to $7.6B with 4% underlying growth, and adjusted EPS rose 8% to $3.29, beating consensus by roughly 2.2%. The quarter introduced a $425M one-time litigation charge tied to the Greenfield Capital collapse and the pending AltamarCAM acquisition, alongside a roughly $5B capital deployment plan including $750M of buybacks. The stock rallied about 4.4% around the print but has drifted about -12.4% since.

Guidance delta

Maintained. Management reaffirmed expectations for continued margin expansion and adjusted EPS growth in 2026, with underlying revenue growth expected similar to 2025 despite pricing headwinds. No material change to guidance.

Key takeaways

  • Revenue rose 8% YoY to $7.6B with 4% underlying growth despite insurance/reinsurance pricing pressure; adjusted EPS grew 8% to $3.29.
  • Executives beat consensus on both lines: EPS of $3.29 vs $3.22 est., and revenue of $7.60B vs $7.41B est.
  • Management framed AI as a core growth pillar across risk, consulting and brokerage, with new tools (ADA, Centrus, GC Quotebox) driving efficiency and new revenue.
  • A $425M one-time litigation charge related to the Greenfield Capital collapse was disclosed in Q1.
  • The pending AltamarCAM acquisition (private-market asset manager, roughly EUR20B AUM) and $750M of buybacks headline a roughly $5B capital deployment plan.
  • Guidance was maintained: management expects underlying revenue growth similar to 2025 and continued margin expansion.

Management priorities

  • Execute the Thrive program to deliver $400M of cost savings.
  • Roll out AI-driven tools including Renewal Companion, Captives Companion and the Marsh Risk Cortex analytics engine.
  • Complete the AltamarCAM acquisition later in 2026 pending regulatory approval.
  • Invest in producer talent and expand in high-growth markets.
  • Balance roughly $5B of capital deployment across M&A opportunism and $750M of share repurchases.

Follow MRSH with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Earnings History

Estimate Beat Miss Match
MRSH REVENUE earnings history estimate and actual scatter chart 5 reported fiscal quarters and 4 future estimate-only quarters. Q2 '25 estimate $7B Q2 '25 actual $7B, beat Q3 '25 estimate $6B Q3 '25 actual $6B, beat Q4 '25 estimate $7B Q4 '25 actual $7B, beat Q1 '26 estimate $7B Q1 '26 actual $8B, beat Q2 '26 estimate $7B Q2 '26 actual $7B, beat Q3 '26 estimate $7B Q4 '26 estimate $7B Q1 '27 estimate $8B Q2 '27 estimate $8B

Analyst Consensus ?

ConsensusHold34 ratings
Bullish1132.4%
Neutral2264.7%
Bearish12.9%

Analyst 52W Price Targets

$173.23Current
$135Low
$201.61Average
$256High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Sep 25, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Morgan Stanley Equal Weight Equal WeightMaintainAug 19, 2026
UBS Buy BuyMaintainJul 27, 2026
Wells Fargo Equal Weight Equal WeightMaintainJul 22, 2026
Mizuho Neutral NeutralMaintainJul 22, 2026
Citigroup Neutral BuyDowngradeJul 22, 2026
Show 29 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $173.23. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
BMO CapitalAnalyst unavailable$203$194.67 +17.2%Aug 25, 2026
Morgan StanleyAnalyst unavailable$200$186.37 +15.5%Aug 19, 2026
UBSAnalyst unavailable$216$184.62 +24.7%Jul 27, 2026
Mizuho SecuritiesYaron Kinar$201$181.59 +16.0%Jul 22, 2026
Wells FargoAnalyst unavailable$188$181.59 +8.5%Jul 22, 2026
See 62 more

Track every rating change on MRSH the moment it posts. Free to start.

Start free

Company context

Snapshot as of publication

Marsh & McLennan Companies, Inc. (MRSH) functions as a leading professional services organization, delivering expert guidance and innovative solutions to clients across the vital domains of risk management, strategic planning, and human capital. Based in New York City, the firm maintains a substantial global workforce, employing approximately 65,000 full-time professionals. This entity serves as the parent company for several prominent advisory and consulting brands.…

Historical context

All MRSH earnings
-0.3%FY2026 Q2 · Calendar Q3 2026

Financial Services peers this season

Latest reports in the same sector
CompanyQuarterEPS surpriseMarket moveHeadline
PUK Prudential plc FY2026 Q2 · Calendar Q3 2026 -40.9% -0.5% Prudential sustains growth and capital returns focus in H1 2026
CM Canadian Imperial Bank of Commerce FY2026 Q3 · Calendar Q3 2026 +8.9% -2.8% CIBC Q3: Broad growth, resilient credit and expanded AI rollout
TD The Toronto-Dominion Bank FY2026 Q3 · Calendar Q3 2026 +13.8% +1.4% TD emphasizes growth investments alongside disciplined capital management
RY Royal Bank of Canada FY2026 Q3 · Calendar Q3 2026 +6.2% -1.3% RBC reports record Q3 earnings while investing for growth
AFRM Affirm Holdings, Inc. FY2026 Q4 · Calendar Q3 2026 +1230.3% +0.3% Affirm's most profitable quarter shifts focus to product execution

Latest beats and misses

Who reports next

Beat on EPS

Missed on EPS

Get the MRSH recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-09-25T15:11:05.393433+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-25T15:11:05.390592+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated · As of 2026-09-25. For educational purposes only; not investment advice.